SWOG Presents 30 Abstracts at ASCO 2023 | SWOG
“Here are highlights from some of the other SWOG work to be presented at ASCO 2023…
- An analysis of the prognostic value of circulating tumor cell (CTC) counts in patients with metastatic hormone-sensitive prostate cancer (mHSPC) on the SWOG S1216 trial reports that CTC count at the start of treatment was highly prognostic of progression-free survival and overall survival, as well as of prostate-specific antigen (PSA) response. The findings suggest baseline CTC count may be a valuable prognostic biomarker in men starting treatment for mHSPC, helping identify those patients likely to respond favorably to treatment and those likely to have longer overall survival times. Dr. Amir Goldkorn, of USC Norris Comprehensive Cancer Center, presents the findings in an ASCO poster session June 3, 8 – 11 am CT (abstract 5080) …
- Also from Dr. Amir Goldkorn’s lab comes a report on the first genomic sequencing panel that performs parallel analysis of single circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from the same blood sample to detect variants relevant to prostate cancer. Known as HERCULES, the panel was developed in collaboration with Thermo Fisher Scientific and validated using samples from patients enrolled to the SWOG S1802 trial in metastatic prostate cancer. Such a tool represents an important breakthrough, as tracking genomic changes over time in metastatic prostate cancer can help guide patient treatment and predict disease outcomes. Daniel Bsteh, PhD, of USC Norris Comprehensive Cancer Center, will present the results in a poster session June 3, 8 – 11 am CT (abstract 5036).”
